LHRH agonists in prostate cancer optimising testosterone control with Eligard®

European Urology, Supplements

Volumn 4, Issue 5, 2005, Pages 1-3

  Schulman, C C ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; HUMAN; LYMPH NODE METASTASIS; MALE; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SHORT SURVEY; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 20344398683     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2005.04.002     Document Type: Short Survey

References (16)

1. Mongiat-Artus P, Teillac P. Role of luteinising hormone releasing hormone (LHRH) agonists and hormonal treatment in the management of prostate cancer. Eur Urol Suppl 2005;4(5):4-13.
2. Messing E, Manola J, Sarosdy M, Wilding G, Crawford D, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003;169(Suppl):396 (abs. 1480).
3. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
4. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-8.
5. Boccon-Gibod L, Bertaccini A, Bono AV, Dev Sarmah B, Holtl W, Mottet N, et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 2003;57(3):187-94.
6. Schroder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, Debois M, et al. Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 2004;172(3):923-7.
7. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79(2):235-46.
8. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000;355(9214):1491-8.
9. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 2005;4(5):14-9.
10. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6): 1021-4.
11. Kawakami J, Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J Urol 2002;167:288 (abstr. 1135).
12. Khan MS, O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 1998;60(1):33-40.
13. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 1998;60(Suppl 2):18-24.
14. Berges R. Eligard1: pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur Urol Suppl 2005;4(5):20-5.
15. Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24(11):1902-14.
16. Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168(3):1199-203.